Archive · 23 Jul 2025
Dr. Reddy's Reports a Slight Rise in Q1 FY26 Profit
Dr. Reddy's, a drug company, made a bit more money this past quarter.
They earned ₹1,409 crore, up slightly from last year.
They made more money overall because they sold more products, especially in Europe, India, and other countries.
However, they made less in North America because the prices of some medicines went down.
They also launched some new products and had some inspections from the US government about their factories.
The company plans to keep working on new products and may buy other companies to grow.
Dr. Reddy's Q1 FY26 net profit increased marginally by 1% to ₹1,409 crore.
Revenue grew 11% to ₹8,545 crore, driven by growth in Europe, India, and emerging markets.
North American revenue decreased by 11% due to price erosion, particularly for Lenalidomide.
The company launched five new products in the US and one new ANDA filing with the USFDA.
Dr. Reddy's received Form 483 observations from USFDA for its facilities in New York and Telangana.
- Who
- Dr. Reddy's Laboratories.
- What
- Dr. Reddy's Q1 FY26 financial results were announced.
- When
- The first quarter ended June 30, 2025; the results were published on July 23, 2025.
- Where
- Hyderabad-based company with operations globally, including North America, Europe, India and emerging markets.
- Why
- Driven by various factors including product launches, price increases, and market performance.
Company Strategy
Market Factors
Future Plans
Company Strategy
Focusing on productivity and investing in innovative products.
Market Factors
N/A
- Net Profit Q1 FY26
- ₹1,409 crore
- Revenue Q1 FY26
- ₹8,545 crore
- Revenue Growth
- 11%
- North America Revenue Decline
- 11%
- Europe Revenue Growth
- 140%
- India Revenue Growth
- 11%
- Emerging Markets Revenue Growth
- 18%